Clinical studies of ABMT in acute myeloid leukaemia.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000276:immunology; D006098:Granulocytes / Q000276:immunology / Q000473:pathology; D006684:HLA-DR Antigens; D006412:Hematopoietic Stem Cells / Q000276:immunology / Q000473:pathology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014181:Transplantation Immunology; D014182:Transplantation, Autologous / Q000009:adverse effects; D014916:Whole-Body Irradiation
D000970:Antineoplastic Agents; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; D003520:Cyclophosphamide; D002066:Busulfan; D008558:Melphalan